OPTHEA LTD (SP.ADR/8) Total Liabilities
OPTHEA LTD (SP.ADR/8) total liabilities. Based on the latest financial reports, OPTHEA LTD (SP.ADR/8) (UKJ2) has total liabilities worth €314.48 Million EUR (≈ $367.65 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See OPTHEA LTD (SP.ADR/8) liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of OPTHEA LTD (SP.ADR/8) (2022–2025)
Total liabilities of OPTHEA LTD (SP.ADR/8) from 2022 to 2025. This chart illustrates how OPTHEA LTD (SP.ADR/8)'s total liabilities have evolved over time, based on quarterly financial data.
OPTHEA LTD (SP.ADR/8) Competitors by Total Liabilities
The table below lists competitors of OPTHEA LTD (SP.ADR/8) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Park Aerospace Corp
NYSE:PKE
|
USA | $11.51 Million |
|
Brandywine Realty Trust
NYSE:BDN
|
USA | $2.84 Billion |
|
EV MOTORS, S.A.
MC:EBROM
|
Spain | €419.19 Million |
|
Concrete Pumping Holdings Class A
NASDAQ:BBCP
|
USA | $615.40 Million |
|
YaGuang Technology Group Co Ltd
SHE:300123
|
China | CN¥3.25 Billion |
|
Kunshan Top A Intelligent Equipment
SHE:300836
|
China | CN¥788.71 Million |
|
Monalisa Group Co Ltd Class A
SHE:002918
|
China | CN¥3.74 Billion |
|
Tianjin Keyvia Electric Co Ltd
SHE:300407
|
China | CN¥1.78 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down OPTHEA LTD (SP.ADR/8)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see OPTHEA LTD (SP.ADR/8) (UKJ2) total assets.
Liquidity & Leverage Metrics
OPTHEA LTD (SP.ADR/8) Total Liabilities Ratios Explained
OPTHEA LTD (SP.ADR/8) total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OPTHEA LTD (SP.ADR/8)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OPTHEA LTD (SP.ADR/8) (2022–2025)
The table below shows the annual total liabilities of OPTHEA LTD (SP.ADR/8) from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €257.87 Million ≈ $301.47 Million |
-2.54% |
| 2024-06-30 | €264.60 Million ≈ $309.35 Million |
+153.22% |
| 2023-06-30 | €104.49 Million ≈ $122.17 Million |
+765.76% |
| 2022-06-30 | €12.07 Million ≈ $14.11 Million |
-- |
About OPTHEA LTD (SP.ADR/8)
Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME).… Read more